VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer’s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:
BofA Securities 2021 Virtual Health Care Conference, May 13, 2021, at 8:45 AM ET
Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aß
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:
Lucara Reports Voting Results From Annual Meeting
VANCOUVER, BC, May 11, 2021 /PRNewswire/ (TSX: LUC) (BSE: LUC) (Nasdaq Stockholm: LUC)
Lucara Diamond Corp. ( Lucara or the Company ) held its Annual General Meeting of shareholders in Vancouver, British Columbia today. Shareholders voted as follows on the matters before the meeting: View PDF Version.
Board Members
Shareholders elected the following 7 board members with shareholders represented at the meeting voting in favour of individual directors as follows:
Director
Advisory Resolution on Executive Compensation
Management s approach to executive compensation, also disclosed in Lucara s management proxy circular dated March 19, 2021 was approved with 96.95% of shares represented at the meeting voting in favour.
Press release content from Business Wire. The AP news staff was not involved in its creation.
IFF Reports First Quarter 2021 Results
May 10, 2021 GMT
NEW YORK (BUSINESS WIRE) May 10, 2021
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the first quarter ended March 31, 2021.
Management Commentary
“We delivered solid first quarter financials, achieving top and bottom-line growth, against a strong year-ago comparison in our first quarter as a combined company,” said IFF Chairman and CEO Andreas Fibig. “Our results are indicative of strong execution by our global team and our best-in-class portfolio of industry-leading solutions. We are also encouraged by the progress we’ve made towards our integration efforts as we are on track to deliver our previously communicated objectives.”
Duraco Specialty Tapes, an OpenGate Capital Portfolio Company, Names Ed Byczynski as Chief Executive Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.